These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25633420)

  • 1. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.
    Flamm RK; Mendes RE; Hogan PA; Ross JE; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):283-9. PubMed ID: 25633420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
    Farrell DJ; Mendes RE; Ross JE; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
    Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Summary of
    Pfaller MA; Mendes RE; Streit JM; Hogan PA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
    Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3684-90. PubMed ID: 21670176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
    Flamm RK; Mendes RE; Hogan PA; Streit JM; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2273-80. PubMed ID: 26833165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States resistance surveillance results for linezolid (LEADER Program for 2007).
    Jones RN; Ross JE; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
    Mendes RE; Flamm RK; Hogan PA; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2014; 58(2):1243-7. PubMed ID: 24323470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China.
    Tian Y; Li T; Zhu Y; Wang B; Zou X; Li M
    BMC Microbiol; 2014 Nov; 14():292. PubMed ID: 25420718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
    Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus.
    Swenson JM; Tenover FC
    J Antimicrob Chemother; 2002 May; 49(5):845-50. PubMed ID: 12003982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.